In Parkinson’s disease, MCC950 treatment significantly decreased the NLRP3 and caspase-1 in the substantia nigra of the brain and elevated the level of the dopamine metabolite 3,4-Dihydroxyphenylacetic acid [37]. Here, NLRP3 is linked to Parkinson disease.